Table 1 Clinical trials and condition of PRMT, EZH2, LSD1, HDAC and DNMT1 inhibitors
From: Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy
Category | Drug | NCT number | Study title | Condition | Status | Phase |
|---|---|---|---|---|---|---|
PRMT inhibitors | GSK3368715 | NCT03666988 | First Time in Humans (FTIH) Study of GSK3368715 in Participants with Solid Tumors and DLBCL | Neoplasms | Recruiting | Phase 1 |
GSK3326595 | NCT02783300 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Neoplasms | Recruiting | Phase 1 | |
NCT03614728 | Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and AML | Neoplasms | Recruiting | Phase 1 | ||
EZH2 inhibitors | Tazemetostat | NCT02860286 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | Mesothelioma, BAP1 Loss of Function | Completed | Phase 2 |
NCT02220842 | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and DLBCL | Lymphoma | Completed | Phase 1 | ||
NCT03010982 | Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B Cell Lymphomas or Adv Solid Tumors | Several Types of Lymphoma, Advanced Solid Tumors | Completed | Phase 1 | ||
CPI-1205 | NCT02395601 | A Study Evaluating CPI-1205 in Patients With B Cell Lymphomas | B Cell Lymphoma | Completed | Phase 1 | |
GSK2816126 | NCT02082977 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory DLBCL, Transformed Follicular Lymphoma, Other NHLs, Solid Tumors and MM | Cancer, Neoplasms | Terminated | Phase 1 | |
LSD1 inhibitors | GSK2879552 | NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma (SCLC) | SCLC | Terminated | Phase 1 |
NCT02929498 | Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk MDS | MDS | Terminated | Phase 1/2 | ||
NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With AML | AML | Terminated | Phase 1 | ||
Tranylcypromine (TCP) | NCT02273102 | Study of TCP-ATRA for Adult Patients With AML and MDS | AML, MDS | Completed | Phase 1 | |
NCT02261779 | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible | AML | Unknown | Phase 1/2 | ||
NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With TCP | AML, MDS | Recruiting | Phase 1/2 | ||
HDAC inhibitors | Vorinostat | NCT00918489 | Study on Efficacy and Tolerability of Virinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) (SAHA-I) | STS | Completed | Phase 2 |
NCT00735826 | A Clinical Trial to Validate Molecular Targets of Virinostat in Patients With Aerodigestive Tract Cancer | Aerodigestive Tract Cancer, Lung Cancer, Esophageal Cancer, Head and Neck Cancer | Completed | Not Applicable | ||
Abexinostat | NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Renal Cell Carcinoma | Active, not recruiting | Phase 3 | |
Panobinostat | NCT01336842 | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Solid Tumors, NSCLC | Completed | Phase 1 | |
DNMT1 inhibitors | 5'-Azacytidine (azacytidine) | NCT02940483 | Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma (5-AZA) | Brain Tumor Recurrent | Completed | Early Phase 1 |
NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With AML Who Are Ineligible for Standard Induction Therapy | AML | Active, not recruiting | Phase 3 | ||
Decitabine | NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | Breast Cancer | Recruiting | Phase 2 | |
NCT04252248 | Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage | Head and Neck Cancer, Anogenital Cancer | Recruiting | Phase 1 | ||
NCT02961101 | Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | Multiple Malignancies | Recruiting | Phase 1/2 |